Table 4 Dosimetric changes affected by tumor regression and baseline obstructive pneumonitis/atelectasis
Variables | Relative change (median) # | Proportion of patients achieving above 5% reduction/increase* | ||
|---|---|---|---|---|
Tumor regression [quick(n = 13) vs. slow(n = 14)] | Obstructive pneumonitis/atelectasis [Yes(n = 11) vs. No(n = 16)] | Tumor regression [quick(n = 13) vs. slow(n = 14)] | Obstructive pneumonitis/atelectasis [Yes(n = 11) vs. No(n = 16)] | |
PTV-GTV | ||||
 V51 | 0.2% vs. -0.7%(P = 0.185) | −0.3% vs. -0.1%(P = 0.394) | 7.7% vs. 14.3%(P = 0.593) | 10% vs. 11.8%(P = 0.89) |
 D95 | 0.3% vs. -0.1%(P = 0.867) | −0.05% vs. 0.4%(P = 0.942) | 0% vs. 7.1%(P = 0.335) | 10% vs. 0%(P = 0.192) |
Total lung | ||||
 Dmean | 2.2% vs. 0.2%(P = 0.009) | 2.3% vs. 0.4%(P = 0.023) | 7.7% vs. 0%(P = 0.299) | 9.1% vs. 0%(P = 0.228) |
 V20 | 2.7% vs. 0.5%(P = 0.006) | 3.3% vs. 0.9%(P = 0.110) | 23.1% vs. 0(P = 0.061) | 9.1% vs. 12.5%(P = 0.786) |
 V30 | 3.5% vs. 0.2%(P = 0.022) | 3.9% vs. 0.2%(P = 0.039) | 38.5% vs. 7.1%(P = 0.055) | 36.4% vs. 12.5%(P = 0.150) |
Esophagus | ||||
 Dmean | 2.2% vs. 0.2%(P = 0.009) | 2.3% vs. 0.4%(P = 0.023) | 7.7% vs. 0%(P = 0.299) | 9.1% vs. 0%(P = 0.228) |
 Dmax | 4.0% vs 5.0%(P = 0.239) | 3.2% vs. 4.8%(P = 0.272) | 23.1% vs. 50%(P = 0.155) | 27.3% vs. 43.8%(P = 0.393) |
Heart | ||||
 Dmean | 0.1% vs. 0.8%(P = 0.488) | 3.9% vs. 0.2%(P = 0.251) | 38.5% vs. 0%(P = 0.012) | 36.4% vs. 6.3%(P = 0.046) |
 V30 | −5.2% vs. -1.7%(P = 0.375) | 8.1% vs. -5.2%(P = 0.162) | 38.5% vs. 14.3%(P = 0.16) | 54.5% vs. 6.3%(P = 0.006) |
 V40 | −16.1% vs. -5.7%(P = 0.458) | 2.1% vs. -16.1%(P = 0.272) | 30.8% vs. 28.6%(P = 0.902) | 45.5% vs. 18.8%(P = 0.143) |